Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo Pharmaceuticals and Bioniche Life Sciences plan for peer-reviewed presentation of interim efficacy and safety results of the first Phase III trial of Urocidin or EN3348.
Subscribe to our email newsletter
Urocidin is a formulation of MCC, a sterile mycobacterial cell wall-DNA complex composition that acts dually to stimulate immunity as well as exert direct anticancer activity, and is indicated as a treatment of bladder cancer.
The trial aimed to evaluate the efficacy and safety of Urocidin in patients with non-muscle-invasive bladder cancer (NMIBC) who are refractory to intravesical BCG (Bacillus Calmette-Guerin) therapy and at high risk of progression.
Results showed an overall one-year disease-free survival rate of 25 percent in the treatment of such bladder cancers.
The first abstract and poster summaries of such results will be released during the Annual Congress of the European Association of Urology (EAU) in Vienna, Austria in the month of March.
Further disclosure of trial results is scheduled for a podium presentation at the annual American Urological Association (AUA) meeting in Washington, D.C during May.
Endo Pharmaceuticals is a US-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics.
Bioniche Life Sciences is a Canada-based research and technology-driven biopharmaceutical company dealing with proprietary products for human and animal health markets worldwide.